Please login to the form below

Not currently logged in
Email:
Password:

company strategy

This page shows the latest company strategy news and features for those working in and with pharma, biotech and healthcare.

Ex-Pharmacyclics CEO invests $25m in Summit

Ex-Pharmacyclics CEO invests $25m in Summit

says his involvement comes because he holds the company’s “management team and…strategy for developing innovative antibiotics for patients with serious infectious diseases in high-regard.”. ... The $25m investment in Summit is a relatively minor

Latest news

  • Circassia seeks shift to AIM after failing LSE criteria Circassia seeks shift to AIM after failing LSE criteria

    The drug developer is planning to move to the AIM after failing to get its ‘free float’ – shares held by investors independent of the company – above the LSE’s required level ... The UK biotech insists there are benefits to moving to the AIM,

  • Boehringer bolts on another immuno-oncology company Boehringer bolts on another immuno-oncology company

    The original terms of the collaboration gave Boehringer an option to buy the company after phase I trials had been completed, but it’s taken the leap while VSV-GP is ... The company currently has clinical-phase projects ranging across checkpoint

  • Boehringer beefs up biologics capacity with €230m investment Boehringer beefs up biologics capacity with €230m investment

    The biologicals development centre (BDC) will be sited at Boehringer’s campus in Biberach which houses a sizeable chunk of the company’s R&D activities, as well as being on ... The project is “another key building block supporting the company’s

  • FDA turns down Celgene’s filing for multiple sclerosis drug FDA turns down Celgene’s filing for multiple sclerosis drug

    chief executive Mark Alles on a conference call yesterday evening when he said the drug is an important part of the company’s “diversification and growth strategy”. ... The company said on the call they did not think the FDA’s position related to

  • CDC backs GSK’s Shingrix over Merck & Co’s Zostavax CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

    approved in the US earlier this month and is a key component of the company’s commercial strategy in the next few years with sales expected to exceed £1bn (around ... the company took a dive.

More from news
Approximately 51 fully matching, plus 122 partially matching documents found.

Latest Intelligence

  • New models of NHS care – new models of pharma response? New models of NHS care – new models of pharma response?

    Novartis’ collaborative culture. Fiona Bride. Fiona Bride, Director of Market Access Strategy, Novartis, says her company has shifted its culture to try to align as much as possible with healthcare providers,

  • How pharma should navigate Artificial Intelligence (AI) How pharma should navigate Artificial Intelligence (AI)

    Leaders need to develop an AI strategy that cuts through the hype and matches each company’s unique situation’. ... Given its clear benefits, leaders need to develop an AI strategy that cuts through the hype and matches each company’s unique

  • Revenue down the back of the beanbag Revenue down the back of the beanbag

    Transparency of the long-term business strategy, communication of company performance and creation of vehicles for shared wealth generation (such as well-designed bonus schemes and all employee stock plans) will ... so. Assuming that a graduate or

  • Understanding HCPs to build a meaningful brand Understanding HCPs to build a meaningful brand

    Net sentiment is the total of all such sentiment values assigned to mentions of the company. ... All those patients and HCPs that were among the most-mentioned Twitter accounts by pharmaceutical companies were also involved with the companies offline,

  • Healthcare Glossary

    A company's strategy in creating and maintaining customers in a specific area.

More from intelligence
Approximately 4 fully matching, plus 33 partially matching documents found.

Latest appointments

  • Chameleon reveals new leadership line-up Chameleon reveals new leadership line-up

    He will report into Matt D’Auria, chief executive of Chameleon’s parent company Healthcare Consultancy Group. ... The company’s US executive vice president of commercial development, Guy Slatcher now moves into the role of president, Chameleon US.

  • Exelixis appoints Andrew Peters to newly created position Exelixis appoints Andrew Peters to newly created position

    In this newly created role, Peters will work with the Exelixis leadership team to refine the company’s mid- and long-term strategy, which is focused on advancing the next generation ... team as we work to identify potential future growth opportunities

  • Sue Mahony to retire as president of Lilly Oncology Sue Mahony to retire as president of Lilly Oncology

    She also most recently led the refocusing of the company’s oncology R&D strategy. ... Prior to this, as senior vice president of human resources and diversity, Mahony played in a role in restructuring the company into business units.

  • Neurimmune appoints chief business officer Neurimmune appoints chief business officer

    Fabian Buller will further drive the biopharma’s growth strategy. Monoclonal antibody-focused Neurimmune has appointed Fabian Buller into the newly created role of chief business officer. ... Roger Nitsch, president and CEO of Neurimmune, said: “We

  • PureTech Health appoints new chief financial officer PureTech Health appoints new chief financial officer

    During his 11 years at the company, Muijrers’ responsibilities saw him help several companies strengthen its biopharmaceutical status. ... In his new role, Muijrers will be take the helm of all aspects of the company’s finances, including capital

More from appointments
Approximately 0 fully matching, plus 61 partially matching documents found.

Latest from PMHub

  • Practical Patient Centricity

    about their medicine is alien to us”.It is not just company strategy and intent that is the driving force for a more patient centric approach: external pressure is also building ... These may be outside the current scope of the company’s business, so

  • GK Strategy

    View LinkedIn profile. Edward Jones. Account Manager. View LinkedIn profile.  . GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? ... Read the full report here. “Lifeways Group and GK Strategy

  • IMARC Group

    IMARC is a leading market research company that offers management strategy and market research worldwide. ... Company Details.

  • Healthcare in the Digital Age

    also global director customer insights and strategy at medical device company Thermo Fisher Scientific.“Over the last ten years, pharmaceutical companies have become more selective, and did more and more segmentation

  • From ideals to execution – exploring the realities of patient-centricity

    We ran a 2-week online expert panel earlier this year, inviting our panel to discuss, as openly as possible, their company vision, the strategy and structure that they were putting

More from PMHub
Approximately 0 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics